Phase 1, Dose-Escalation, Open-label, Safety and Pharmacokinetic, First in Human Study of BXQ-350 Administered as a Single Agent by Intravenous Infusion in Adult Patients With Advanced Solid Tumors and Recurrent High-Grade Gliomas

Trial Profile

Phase 1, Dose-Escalation, Open-label, Safety and Pharmacokinetic, First in Human Study of BXQ-350 Administered as a Single Agent by Intravenous Infusion in Adult Patients With Advanced Solid Tumors and Recurrent High-Grade Gliomas

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Saposin C (Primary)
  • Indications Glioblastoma; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Bexion Pharmaceuticals
  • Most Recent Events

    • 01 Nov 2017 According to a Bexion Pharmaceuticals media release, the company has initiated the phase Ib portion of this trial. The highest dose is being utilized in the Phase 1b trial continuing at all four sites.
    • 06 Sep 2017 According to a Bexion Pharmaceuticals media release, the highest dose tested in phase 1a trial will be used in phase1b part of this trial.
    • 05 Sep 2017 According to a Bexion Pharmaceuticals media release, the phase Ia portion of this trial has been completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top